ClinicalTrials.gg
CompletedNCT03329638Updated Aug 26, 2020

A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)

A Phase 2 interventional study of DE-127 Ophthalmic Solution low dose and DE-127 Ophthalmic Solution medium dose in Myopia, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 1 site in Singapore. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-08-26.

Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Myopia with a site in Singapore — 11 open to participants now, 16 under way, 2 of them phase 3. Myopia · Singapore.

Enrollment
16th of 35
99 · median 80
Started
2017
with 2 others
Phase 2
Only one
of the 43
Registered
18th of 43
by date

Among the 43 studies in Myopia with a site in Singapore, this one is the 16th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2017, is the only one in phase 2, and was the 18th registered.

Myopia

1,163 studies on the registry are indexed under Myopia; 227 are open to participants now.

Browse Myopia studies →

Open to participants now

11 of the 43 studies in Myopia with a site in Singapore are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 120 Myopia studies recruiting now, 19 (16%) set no upper age limit and 100 (83%) stop at 75 or younger; 84 take children under 18; 52 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myopia with a site in Singapore, or all of them as a file.
02

Study summary

To investigate the safety and efficacy of three concentrations of DE-127 ophthalmic solution when compared to Placebo in subjects diagnosed with mild or moderate myopia.

To investigate the dose response of DE-127.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Refractive error of spherical equivalent -1.0 diopter to -6.0 diopter in both eyes
  • Anisometropia of spherical equivalent less than or equal to 1.50 diopter in both eyes
  • Distance vision correctable to logMAR 0.2 or better in both eyes
  • Normal intraocular pressure of not greater than 21 mmHg in both eyes
  • No allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride

Exclusion criteria

Exclusion Criteria:

  • Amblyopia or manifest strabismus including intermittent tropia
  • Ocular disorders that potentially affect myopia or refractive power
  • Previous or current use of contact lenses, bifocal lenses, progressive addition lenses, or other forms of treatment (including atropine and pirenzepine) for myopia
  • Systemic disorders that potentially affect myopia or refractive power
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    DE-127 Ophthalmic Solution low dose

    Drug: DE-127 Ophthalmic Solution low dose

  • Experimental
    DE-127 Ophthalmic Solution medium dose

    Drug: DE-127 Ophthalmic Solution medium dose

  • Experimental
    DE-127 Ophthalmic Solution high dose

    Drug: DE-127 Ophthalmic Solution high dose

  • Placebo comparator
    Placebo Ophthalmic Solution

    Drug: Placebo Ophthalmic Solution

Interventions

  • DrugDE-127 Ophthalmic Solution low dose

    Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

  • DrugDE-127 Ophthalmic Solution medium dose

    Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

  • DrugDE-127 Ophthalmic Solution high dose

    High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

  • DrugPlacebo Ophthalmic Solution

    Placebo Ophthalmic Solution dosed once daily for 12 months

06

What researchers measure

Primary outcomes

  1. Spherical equivalent

    Change from Baseline in spherical equivalent determined by cycloplegic autorefraction at Month 12 in the study eye.

    Time frame: Month 12

07

Study locations

1 site
  • Singapore National Eye Centre
    Singapore, Singapore
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Sep 2019, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2017
First posted
Nov 6, 2017
StartActual
Oct 27, 2017
Primary completionActual
Sep 12, 2019
CompletionActual
Apr 9, 2020
Last update
Aug 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03329638
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Oct 27, 2017
Primary completion
Sep 12, 2019
Completion
Apr 9, 2020
Last update
Aug 26, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion